<DOC>
	<DOCNO>NCT01588496</DOCNO>
	<brief_summary>A study determine safety , tolerability , efficacy evolocumab ( AMG 145 ) patient homozygous familial hypercholesterolemia ( HoFH ) .</brief_summary>
	<brief_title>Trial Evaluating PCSK9 Antibody Subjects With LDL Receptor Abnormalities</brief_title>
	<detailed_description>Study Masking : Part A : Open Label Part B : Double Blind</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Males female ≥ 12 ≤ 80 year age Diagnosis homozygous familial hypercholesterolemia Stable lipidlowering therapy least 4 week LDL cholesterol ≥ 130 mg/dl ( 3.4 mmol/L ) Triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) Bodyweight ≥ 40 kg screening . LDL plasma apheresis within 8 week prior randomization New York Heart Association ( NYHA ) class III IV last known leave ventricular ejection fraction &lt; 30 % Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month randomization Planned cardiac surgery revascularization Uncontrolled cardiac arrhythmia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>familial hypercholesterolemia</keyword>
	<keyword>homozygous familial hypercholesterolemia</keyword>
</DOC>